Biopharmaceutics Classification System Class IV Drugs: Carriers and Barriers

Within the Biopharmaceutics Classification System (BCS), Class IV compounds exhibit both low aqueous solubility and low intestinal permeability, placing these compounds among the most formidable challenges in pharmaceutical development. These molecules are frequently subject to efflux–transporter interactions, most notably with P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP), and undergo extensive pre-systemic cytochrome P450 (CYP450) metabolism, collectively producing poor and erratic oral bioavailability (BA). This review provides a structured narrative synthesis of representative literature on formulation strategies for BCS IV drug delivery. Coverage spans solubility-enhancing and solid-state engineering technologies (cyclodextrins, amorphous solid dispersions, cocrystals, supersaturating systems), lipid-based and nanotechnology-based delivery platforms, transporter- and metabolism-targeted prodrug and permeation–enhancer strategies, alternative administration routes, and computational design tools. Notable marketed successes including Norvir® (ritonavir), Kaletra® (lopinavir), Neoral® (cyclosporine), Venclexta® (venetoclax), and Abraxane® (nab-paclitaxel) demonstrate that BCS IV classification need not preclude clinical and commercial success. This review consolidates and organises these strategies within a unified decision framework intended to serve as a comprehensive resource for pharmaceutical scientists formulating BCS IV compounds. Throughout, this review foregrounds an asymmetry too often left implicit: low solubility is mechanistically well-understood and reliably correctable, whereas the permeability barrier raises three harder questions: whether in vitro permeability predicts in vivo permeability, whether deliberately altering intestinal permeability carries a toxicological cost, and whether most strategies change permeability at all rather than raising exposure by other means.